- Browse by Subject
Browsing by Subject "Tumor necrosis factor-alpha"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Hepatotoxicity Associated with the Use of Anti-TNF-α Agents(Springer, 2016-03) French, Joshua B.; Bonacini, Maurizio; Ghabril, Marwan; Foureau, David; Bonkovsky, Herbert L.; Department of Medicine, IU School of MedicineMedications to inhibit the actions of tumour necrosis factor alpha have revolutionized the treatment of several pro-inflammatory autoimmune conditions. Despite their many benefits, several serious side effects exist and adverse reactions do occur from these medications. While many of the medications' potential adverse effects were anticipated and recognized in clinical trials prior to drug approval, several more rare adverse reactions were recorded in the literature as the popularity, availability and distribution of these medications grew. Of these potential adverse reactions, liver injury, although uncommon, has been observed in some patients. As case reports accrued over time and ultimately case series developed, the link became better established between this family of medicines and various patterns of liver injury. Interestingly, it appears that the majority of cases exhibit an autoimmune hepatitis profile both in serological markers of autoimmune liver disease and in classic autoimmune features seen on hepatic histopathology. Despite the growing evidence of this relationship, the pathogenesis of this reaction remains incompletely understood, but it appears to depend on characteristics of the medications and the genetic composition of the patients; it is likely more complicated than a simple medication class effect. Because of this still incomplete understanding and the infrequency of the occurrence, treatments have also been limited, although it is clear that most patients improve with cessation of the offending agent and, in certain cases, glucocorticoid use. However, more needs to be done in the future to unveil the underlying mechanisms of this adverse reaction.Item Mapping cardiac remodeling in chronic kidney disease(American Association for the Advancement of Science, 2023) Kaesler, Nadine; Cheng, Mingbo; Nagai, James; O’Sullivan, James; Peisker, Fabian; Bindels, Eric M. J.; Babler, Anne; Moellmann, Julia; Droste, Patrick; Franciosa, Giulia; Dugourd, Aurelien; Saez-Rodriguez, Julio; Neuss, Sabine; Lehrke, Michael; Boor, Peter; Goettsch, Claudia; Olsen, Jesper V.; Speer, Thimoteus; Lu, Tzong-Shi; Lim, Kenneth; Floege, Jürgen; Denby, Laura; Costa, Ivan; Kramann, Rafael; Medicine, School of MedicinePatients with advanced chronic kidney disease (CKD) mostly die from sudden cardiac death and recurrent heart failure. The mechanisms of cardiac remodeling are largely unclear. To dissect molecular and cellular mechanisms of cardiac remodeling in CKD in an unbiased fashion, we performed left ventricular single-nuclear RNA sequencing in two mouse models of CKD. Our data showed a hypertrophic response trajectory of cardiomyocytes with stress signaling and metabolic changes driven by soluble uremia-related factors. We mapped fibroblast to myofibroblast differentiation in this process and identified notable changes in the cardiac vasculature, suggesting inflammation and dysfunction. An integrated analysis of cardiac cellular responses to uremic toxins pointed toward endothelin-1 and methylglyoxal being involved in capillary dysfunction and TNFα driving cardiomyocyte hypertrophy in CKD, which was validated in vitro and in vivo. TNFα inhibition in vivo ameliorated the cardiac phenotype in CKD. Thus, interventional approaches directed against uremic toxins, such as TNFα, hold promise to ameliorate cardiac remodeling in CKD.